Introduction
The cardiac intercalated disc hosts a molecular network that integrates intercellular adhesion, electrical coupling, and excitability at the site of contact between cardiomyocytes. Disruption of this complex undermines the integrity of the myocardium, as demonstrated by various disease states associated with intercalated disc remodelling. One of these diseases is Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy (ARVD/C), an inherited disorder characterized by ventricular arrhythmias and fibrofatty replacement of predominantly the right ventricular (RV) myocardium. Mutations in genes encoding the cardiac desmosome are identified in the majority of affected patients, 1 although the genetic basis extends beyond desmosomal proteins. [2] [3] [4] Of particular interest in this regard is Na v 1.5, the pore-forming subunit of the voltage-gated cardiac sodium channel. Early studies showed that the desmosomal protein plakophilin-2 (PKP2) co-precipitates with Na v 1.5, and that loss of PKP2 expression alters the amplitude and kinetics of the sodium current (I Na ). 3, 5 Furthermore, mutations in PKP2 have been associated with a sodium channelopathy phenotype, 6 while decreased immunoreactive Na v 1.5 protein has been detected in the majority of human ARVD/C heart samples. 7 These observations indicate a close functional association between Na v 1.5 and mechanical junction proteins. The concept is further validated by observations that Na v 1.5 co-precipitates with the adherens junction protein N-Cadherin, 5 and by super-resolution microscopy studies demonstrating the presence of 'adhesion/excitability' nodes formed by aggregates of Na v 1.5 and N-Cadherin. 8 Likewise, we postulated that mutations in the voltage-gated sodium channel complex may be part of the molecular substrate underlying ARVD/C.
Methods

Study population and molecular genetic screening
We first screened the entire exome for mutations among a 'discovery cohort' of six unrelated Caucasian patients with a clinical diagnosis of ARVD/ C according to the 2010 Task Force Criteria 9 and without mutations in the ARVD/C-associated desmosomal genes (PKP2, DSC2, DSG2, DSP, and JUP). All individuals underwent whole-exome sequencing using the Illumina HiSeq2000 platform. We used the human reference genome GRCh37/hg19 for mapping. 10 Detailed genetic screening methodology for the discovery cohort is described in the Supplementary material online.
We subsequently analysed SCN5A in a multicentre transatlantic 'validation cohort' of 281 unrelated patients who had a clinical diagnosis of ARVD/C according to the 2010 Task Force Criteria 9 and who underwent sequencing for the ARVD/C-associated desmosomal genes (PKP2, DSC2, DSG2, DSP, and JUP). Patients were divided into those with a pathogenic desmosomal mutation (n = 146) and those without a pathogenic desmosomal mutation (n = 135). Pathogenicity of desmosomal mutations was determined as done previously. 11 Most participants were Caucasian (n = 276); four were Asian and one was African American. Detailed genetic screening methodology for the validation cohort is described in the Supplementary material online.
Potentially causal variants were identified using standard filtering criteria. Variants were excluded if they had a minor allele frequency (MAF) >1% in the Exome Aggregation Consortium, Cambridge, MA, Exome Variant Server (release ESP6500SI-V2), or 1000 Genomes Project, and/or if they were present in dbSNP 137. We also excluded all variants with an SIFT score >0.03 and/or a Polyphen2 score of <0.90. Nucleic acid deviations were compared with the reference sequence for SCN5A (NM_198056.2). All mutations were confirmed by Sanger sequencing. The study complies with the Declaration of Helsinki and a locally appointed ethics committee approved the research protocol. Informed consent was obtained from all participants.
Generation of induced pluripotent stem cell-derived cardiomyocytes
We assessed the cellular and molecular phenotype of the SCN5A mutation identified in our discovery cohort [p.Arg1898His (c.5693G > A)] in induced pluripotent stem cell-derived cardiomyocytes (IPSC-CMs) that were derived from the patient's peripheral blood mononuclear cells. Detailed methodology is described in the Supplementary material online. T-cells-enriched peripheral blood mononuclear cells from the patient and two normal controls were used for human IPSC derivation using standard techniques (CytoTune-iPS 2.0 Sendai Reprogramming Kit, Invitrogen, Carlsbad CA, USA). Human IPSC clones were picked, cultured, and expanded on the mouse embryonic fibroblasts while following the manufacturer's instructions.
Whole-cell patch clamping and threedimensional super-resolution fluorescence microscopy
Whole-cell I Na recordings were conducted using standard protocols that are described in the Supplementary material online. In addition, we performed two-colour (Na v 1.5 and N-Cadherin) three-dimensional imaging by direct stochastic optical reconstruction microscopy. Our spatial resolution in the X-Y plane was $20 nm. Detailed methods are described in Leo-Macias et al.
8
; a brief description is provided in the Supplementary material online. 
Genetic correction of the SCN5A mutation in human IPSC-CMs
The p.Arg1898His mutation in patient-specific IPSC-CMs was corrected using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) with CRISPR-associated (Cas9) system, following a recently published protocol. 12 Successful correction of the p.Arg1898His mutation was confirmed by direct sequencing (see Supplementary material online, Figure S1 ), and off-target effects generated by CRISPR-Cas9 were evaluated to confirm that the rescued phenotype is a direct result of the genetic correction (see Supplementary material online, Table S1 ). Successfully corrected cell clones were selected for cardiac differentiation. Detailed methodology is described in the Supplementary material online.
Generation of HEK293 cells
HEK293 cells, derived from human embryonic kidney cells, were used to complement IPSC-CMs experiments. DNA plasmids containing cDNA for human SCN5A or mutant SCN5A-c.5693A were transfected into HEK293 cells using Lipofectamine 2000 reagent (Life Technologies, Carlsbad, CA, USA). Patch clamping was performed 48 h after transfection. Expression of the transfectant was confirmed by western blots for Na v 1.5 using a polyclonal Na v 1.5 antibody (Sigma, St. Louis, MO, USA). Please see the Supplementary material online for more details.
Statistical analysis
Continuous data were presented as mean ± standard deviation or median (inter-quartile range) and categorical variables as numbers (percentages Table S2 includes other variants identified on whole-exome sequencing in this individual, with the factors that led to prioritizing them below SCN5A.
Clinical evaluation
The patient presented at age 29 years with ventricular tachycardia (VT) of left bundle branch block (LBBB) inferior axis morphology after playing soccer. Figure 1 shows a summary of her clinical evaluation. ARVD/C diagnosis was made based on T-wave inversions in V1-2 (minor TFC), RV dyskinesia with RV end-diastolic volume 128 mL/m 2 (major TFC), and LBBB VT (minor TFC Although previous studies have identified this variant in controls, 22, 25 it has also been observed in affected individuals, 27 and a recent study described an abnormal biophysical phenotype that depends on splice variant and pH. leads; a pharmacological sodium blocker challenge was not performed. Family members were not amenable to genetic testing.
Functional characterization: biophysical effect on sodium channel
The consequence of the p.Arg1898His mutation on the biophysical and structural properties of Na v 1.5 was studied in IPSC-CM from the patient's peripheral blood mononuclear cells. Gene editing (CRISPR-Cas9) was used to generate a parallel hIPSC-CM line from the same patient, one in which the histidine in position 1898 was reversed back to arginine (p.Arg1898His reversed to p.Arg1898Arg). Using whole-cell patch clamp, we demonstrated that the peak I Na density of cells carrying p.Arg1898His was 36% reduced when compared with those expressing the wild-type amino acid (p.Arg1898Arg) in the same position (P = 0.002; see Figure 2A ). To document that the change in current amplitude is robust and independent of cell-type, we examined the properties of the sodium current generated by p.Arg1898Arg or p.Arg1898His in an exogenous cell system. For this purpose, we transiently transfected HEK293 cells with cDNA coding for SCN5A. Similar to the IPSC-CMs, the current density generated by a construct containing the SCN5A p.Arg1898His mutation was significantly reduced compared with wildtype SCN5A (p.Arg1898Arg) (P = 0.002; see Figure 2B ). Both in the case of the hIPSC-CMs and in the HEK cells, the steady-state voltage dependence of inactivation was not affected by the mutation (Figure 2C and D) .
Effect of mutation on intercalated disc organization
We examined the effects of the p.Arg1898His SCN5A mutation on intercalated disc organization by three-dimensional super-resolution fluorescence microscopy (3D-SRFM) ( Figure 3) . Cells used for 3D-SRFM were obtained and processed in parallel to those used for the patch clamp experiments. We focused our analysis on cells that showed a striated pattern of a-actinin staining. Data acquisition was limited to areas of cellcell contact positive for N-Cadherin staining ( Figure 3A) . The same two cell populations characterized in terms of I Na density ( Figure 2) were studied. As shown in Figure 3B , the density of protein clusters of both Na V 1.5 (P = 0.0054) and N-Cadherin (P = 0.026) was larger in geneedited cells, whereas cluster size was not dependent on whether arginine or histidine occupied position 1898 of Na v 1.5 (P = 0.126 for Na v 1.5 and P = 0.536 for N-Cadherin; Figure 3C and D). Overall, these results suggest that the p.Arg1898His SCN5A mutation associates with reduced average peak sodium current density and reduced density of Na v 1.5 and N-Cadherin clusters at the site of cell contact.
Validation cohort
To validate the presence of SCN5A variants in ARVD/C patients, we performed sequencing of SCN5A in a multicentre validation cohort of 281 unrelated ARVD/C patients [169 (60%) male, age at presentation 34.8 ± 13.7 years]. Approximately half (n = 135, 48%) of subjects did not harbour a mutation in any of the ARVD/C-associated desmosomal genes; the remainder (n = 146, 52%) carried a pathogenic desmosomal mutation (77% PKP2, see Supplementary material online, Table S3 ).
We identified a putatively pathogenic heterozygous SCN5A variant in 5/281 (1.8%) patients. Prevalence of SCN5A variants was 2.2% (n = 3/ 135) in those without a desmosomal mutation compared with 1.4% (n = 2/146) in those with a desmosomal mutation. A summary of SCN5A variants is shown in Table 1 . All variants were rare (MAF < _ 0.0692%; 4/5 variants with an MAF <0.05%) or novel, occurred in highly conserved region of the sodium channel, and were predicted pathogenic by SIFT and Polyphen2. Table 2 shows detailed clinical data of the five SCN5A mutation carriers. All patients fulfilled ARVD/C diagnosis according to the 2010 diagnostic Task Force Criteria; 9 of note, they all had major structural abnormalities on cardiac imaging. One SCN5A mutation carrier (p.Tyr416Cys) also harboured a variant of uncertain significance in the LMNA gene [p.Arg190Gln (c.569G > A)] (see Table 2 for details). Among SCN5A variant carriers, mean QRS duration was prolonged (119 ± 15 ms), whereas PR and QTc intervals were within normal limits (168 ± 19 and 416 ± 34 ms, respectively). None of the subjects had spontaneous ST-segment elevation. One SCN5A mutation carrier (p.Leu729del) underwent pharmacological sodium channel blocker challenge, which failed to unmask the electrocardiographic pattern of Brugada syndrome at peak intravenous ajmaline dose 1 mg/kg. As shown in Figure 4 , an ARVD/C family history was observed in one SCN5A mutation carrier, in whom the variant (p.Leu729del) co-segregated with the phenotype with reduced penetrance. The other variant carriers did not have a family history of ARVD/C, although cardiac screening was limited.
Comparison of demographics and clinical phenotype by genotype
We compared the demographic and phenotypic characteristics of ARVD/C patients with an SCN5A variant with those with and without a desmosomal mutation. As shown in the Supplementary material online, Table S4 , QRS duration was significantly prolonged in SCN5A variant carriers compared with all other ARVD/C subjects (119 ± 15 ms in SCN5A variant carriers vs. 94 ± 14 ms in others, P < 0.01). There were no significant differences in PR or QTc duration, or in any domain of the Task Force Criteria between the groups.
Discussion
This study represents the largest cohort of ARVD/C patients to date investigated for SCN5A mutations. Using hIPSC-CMs from an ARVD/C patient, we first defined the functional (patch clamp) and structural (3D-SRFM) effects caused by a single SCN5A mutation. Using gene editing, we were able to demonstrate that an amino acid substitution in Na v 1.5 not only has the (somewhat expected) repercussion of changing sodium current amplitude but also causes a structural deficit in the organization of a protein directly relevant to cell-adhesion (N-Cadherin). We subsequently screened 281 ARVD/C patients for SCN5A mutations, and showed that rare variants in SCN5A are present in approximately 2% of ARVD/C patients. Overall, these results support the notion that Na v 1.5 is in a functional complex with cell adhesion molecules, and reveal potential non-canonical mechanisms by which Na v 1.5 dysfunction may contribute to cardiomyopathy.
4.1 SCN5A mutations and Na v 1.5 function
Canonical Na v 1.5 function
Functional analyses were performed in an IPSC-CM cell model containing the SCN5A mutation (p.Arg1898His) observed in our discovery cohort. Super-resolution images show a normal cluster size, but reduced cluster density for Na v 1.5 at the intercalated disc, indicating that Na v 1.5 clusters are less abundant at the membrane. This suggests that the total I Na that can potentially be generated is less, which is indeed confirmed by our whole-cell patch clamping results. Of note, the change in current amplitude was robust, and independent of cell type, as it was reproduced in an exogenous expression system. The p.Arg1898His mutation in our ARVD/C patient localizes to the Na v 1.5 C-terminal domain (CTD), a highly conserved region of the sodium channel that regulates channel function through many auxiliary proteins including Fibroblast Growth Factor 13 (FGF13; also known as fibroblast growth factor homologous factor 2) and calmodulin (CaM). 13 As shown in Figure 5 , the mutated residue in our patient, p.Arg1898, sits at the hinge between the Na v CTD and the IQ domain helix, where it interacts with the side chain of p.Glu1901 in the Na v CTD and forms a cation-p interaction with the side chain of p.Tyr98 in FGF13. p.Tyr98 in FGF13 also interacts with p.Lys95 in CaM. Interestingly, sequence alignments indicate that p.Arg1898 in Na v 1.5 is homologous to p.Arg1902 in Na v 1.2, which, when mutated to Cys, has been associated with familial autism.
14 In Na v 1.2, the p.Arg1902Cys mutation leads to reduced binding of Ca 2þ /CaM and thereby to abnormal Ca 2þ -dependent regulation. 14, 15 It is reasonable to think that a mutation of the equivalent residue in Na v 1.5, p.Arg1898, affects the same set of interactions, and therefore plays a similar role in the development of cardiac disease.
Non-canonical Na v 1.5 function
Although it is not surprising that a Na v 1.5 mutation causes sodium channel dysfunction, it is well recognized that SCN5A mutations may also lead to cardiac structural abnormalities. 16, 17 However, the mechanism by which SCN5A mutations cause cardiomyopathy remains unknown. We recently described the presence of an adhesion/excitability node in cardiac myocytes. 8 In this prior work, we showed that (i) the adherens junction protein N-Cadherin serves as an attractor for Na v 1.5 clusters, (ii) the Na v 1.5 in these clusters are major determinants of the cardiac sodium current, and (iii) clustering of Na v 1.5 facilitates its regulation by molecular partners. In this study, we confirm and expand prior data by showing that Na v 1.5 is in a functional complex with cell adhesion molecules, and that a primary Na v 1.5 defect may affect N-Cadherin biology resulting in reduced size and density of N-Cadherin clusters at the intercalated disc. These results are particularly interesting in the context of prior studies showing that Na v 1.5 is delivered to the membrane via the microtubule network, 18 and that microtubules at the intercalated disc anchor at N-Cadherin-rich sites. 6, 19 Whether Na v 1.5 interacts directly with N-Cadherin, or whether this interaction is mediated through unknown molecular partners remains currently unknown. Further investigation is warranted to establish the role of molecules at the Na v 1.5 CTD in orchestrating the interaction between mechanical and electrical junctions.
Prevalence and clinical implications of SCN5A mutations in ARVD/C
A previous study described SCN5A variants in 1 of 12 Chinese ARVD/C patients. 20 However, clinical data in this study were sparse and analyses
were not corroborated by functional data. Our study shows that approximately 2% of ARVD/C cases harbour putatively pathogenic Table 2) . A pedigree can be found in the Supplementary material online, Figure S2 . Her 33-yearold son had presyncope and palpitations, with frequent ventricular extrasystoles and borderline RV dimensions (RV end-diastolic volume 97. 0 mL/m 2 ). He also harboured the SCN5A, but not the LMNA, variant. Although we cannot exclude the possibility that the LMNA variant contributes to this proband's phenotype, this highlights the well-established finding of multiple mutations in a subset of ARVD/C patients. 1, 21 As per study design, all individuals fulfilled diagnostic TFC for ARVD/C. In addition, each proband with an SCN5A mutation fulfilled major structural TFC for ARVD/C, further supporting the evidence that Na v 1.5 plays a role in cardiac structural integrity. Interestingly, QRS duration was significantly prolonged in SCN5A variant carriers compared with all other subjects, suggestive of a loss-of-function effect of Na v 1.5. Future studies are necessary to determine whether specific management recommendations should be made for ARVD/C patients with SCN5A variants. As in sodium channelopathies, avoidance of sodium channel blocking agents may prove to be prudent.
Implications for understanding of SCN5A pathophysiology
SCN5A mutations have been associated with a variety of clinical phenotypes including Brugada Syndrome, 22 Long QT Syndrome, 23 progressive cardiac conduction disease, 23 dilated cardiomyopathy, 16 and now also ARVD/C. Based on our results, we speculate that Na v 1.5 not only forms ion-selective pores but also is a multifunctional protein in a functional adhesion/excitability complex with mechanical junctions. Depending on the protein interaction affected, genetic changes in Na v 1.5 may thereby cause a predominantly structural phenotype (e.g. dilated cardiomyopathy), predominantly electrical phenotype (e.g. Brugada Syndrome, Long QT syndrome), or mixed electrical and structural phenotype (e.g. ARVD/C). As such, the affected protein interaction, more than the exact gene mutation, may determine the phenotype. Although further investigation is warranted to establish the role of auxiliary proteins in orchestrating the interaction between mechanical and electrical junctions at the intercalated disc, these data provide an additional explanation for the pathophysiological mechanism by which SCN5A mutations may result in cardiomyopathy.
Limitations
Recent studies have indicated that SCN5A has a 2-5% background rate of rare non-synonymous variants, 24 which complicates the interpretation of our results. Although the functional analyses (p.Arg1898His) and cosegregation data (p.Leu729del) in two of our patients support a deleterious, disease-causing effect, we were not able to obtain functional or segregation data for the other patients, However, all these mutations are radical or have previously been associated with disease. 22, [25] [26] [27] [28] [29] Although all individuals in our study underwent genetic testing for the desmosomal genes, one-third [n = 93/281 (33%)] did not undergo whole-exome or large-panel-targeted sequencing, and mutations in genes infrequently associated with ARVD/C cannot be excluded in these individuals. Given the differences in screening methods, the finding of SCN5A variants in our validation cohort should be regarded as 'proof of principle' rather than definite evidence of pathogenicity in a single-gene Mendelian fashion. IPSC-CMs are not fully mature cardiomyocytes: although these cells develop a contractile apparatus, the sarcomeres are disorganized and oriented in multiple directions. Also, IPSC-CMs do not have a proper mature intercalated disc structure connecting adjacent cells. As such, we focused our analysis on protein clusters in the immediate vicinity of the intercellular junction. In addition, it is important to note that statistical analyses on our IPSC-CMs and HEK293 cells are based on only one mutation. Although our study provides a possible explanation for the pathophysiological mechanism underlying structural changes in patients with an SCN5A mutation, it is important to recognize that many cardiac diseases associated with SCN5A do not exhibit structural abnormalities.
Conclusions
The results of our study show that putatively pathogenic SCN5A variants occur in approximately 2% of ARVD/C patients. SCN5A variants are associated with a significantly prolonged QRS duration. In one of our study subjects, we confirm a loss of Na v 1.5 function in two experimental systems. More importantly, we reveal reduced abundance of Na v 1.5 as well as N-Cadherin clusters at the intercalated disc, suggesting that Na v 1.5 is in a functional adhesion/excitability complex with mechanical junctions. Furthermore, our studies demonstrate the utility of the CRISPR/Cas9 technology in the phenotypical characterization of hIPSCCMs containing suspect pathogenic substitutions. Overall, our data provide a novel, alternative explanation as to the pathophysiological mechanisms by which SCN5A mutations may cause a cardiomyopathic phenotype.
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